Total trials
271
Active
21
Phase 3
48
Total enrollment
112,441
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| iPSC-derived RPE/PLGA transplantation | — | — | — | — | — | 1 | |
| Metformin hydrochloride | — | — | — | — | — | 1 |
Next readouts
- 2028-02-02
- 2029-05-31
Top conditions
- Uveitis36
- Macular Degeneration27
- Diabetic Retinopathy21
- Age-Related Macular Degeneration20
- Cataract20
- Retinal Disease14
- Retinitis Pigmentosa13
- Eye Diseases9
Frequently asked questions about National Eye Institute (NEI)
- How many clinical trials does National Eye Institute (NEI) have on ClinicalTrials.gov?
- National Eye Institute (NEI) is listed as the lead sponsor on 271 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Eye Institute (NEI)'s trials are in Phase 3?
- 48 of National Eye Institute (NEI)'s trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does National Eye Institute (NEI) focus on?
- National Eye Institute (NEI)'s most-studied conditions on ClinicalTrials.gov are Uveitis, Macular Degeneration, Diabetic Retinopathy, Age-Related Macular Degeneration, Cataract.
- When are National Eye Institute (NEI)'s next clinical trial readouts?
- National Eye Institute (NEI) has 2 upcoming primary-completion readouts tracked here; the soonest is “Oral Metformin for Treatment of ABCA4 Retinopathy”, expected around 2028-02-02.